Fannie Mae, Freddie Mac shares tumble after conservatorship comments
David J. Katzoff, the Chief Financial Officer of Alzamend Neuro , Inc. (NASDAQ:ALZN), recently purchased 5,000 shares of the company’s common stock. The transaction, which took place on March 21, 2025, was executed at an average price of approximately $1.0096 per share, resulting in a total value of $5,048. The purchase comes as the stock shows strong momentum, with a 13% gain over the past week. According to InvestingPro analysis, the company appears undervalued at its current market cap of $6.66M.
Following this acquisition, Katzoff now directly owns a total of 5,540 shares in Alzamend Neuro. This purchase reflects Katzoff’s ongoing involvement and investment in the pharmaceutical company, which focuses on developing treatments for Alzheimer’s disease and other neurodegenerative conditions. InvestingPro data shows the company maintains a healthy current ratio of 5.44, indicating strong short-term liquidity. Get access to 12 more exclusive ProTips and comprehensive financial metrics with InvestingPro.
In other recent news, Alzamend Neuro has announced several significant developments. The company reported amendments to its corporate bylaws and introduced a new series of convertible preferred stock, Series C, aimed at enhancing financial flexibility. This follows an agreement with a sophisticated investor to exchange shares of Series A Convertible Preferred Stock for Series C shares and to sell up to 500 shares of Series C Preferred Stock. The Series C Preferred Stock carries a stated value of $10,000 per share and offers a 15% annual dividend, with preferential rights in the event of liquidation. Additionally, Alzamend Neuro has completed a specialized head coil for its upcoming Phase II clinical trials, which will assess the pharmacokinetics of their product AL001 compared to traditional lithium carbonate. These trials, conducted in collaboration with Massachusetts General Hospital, aim to optimize lithium distribution in the brain for treating neurological and psychiatric conditions. The company believes the head coil will provide valuable insights into lithium’s interactions within the brain, potentially expanding its therapeutic applications. These developments represent Alzamend Neuro’s ongoing efforts to advance its research and secure funding for its operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.